We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
-2.91%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
-$30M
(-18%)
Cap. Flow
-$21.6M
Cap. Flow
% of AUM
-15.92%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
262
New
34
Increased
55
Reduced
87
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enovis
ENOV
|
+$1.04M |
| 2 |
Amphastar Pharmaceuticals
AMPH
|
+$1.04M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$958K |
| 4 |
Invesco NASDAQ 100 ETF
QQQM
|
+$955K |
| 5 |
Sarepta Therapeutics
SRPT
|
+$929K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UroGen Pharma
URGN
|
+$2.16M |
| 2 |
Corcept Therapeutics
CORT
|
+$2.14M |
| 3 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
+$2.13M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$1.49M |
| 5 |
Perspective Therapeutics
CATX
|
+$1.35M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.25% |
| 2 | Real Estate | 12.98% |
| 3 | Financials | 6.42% |
| 4 | Industrials | 2.59% |
| 5 | Technology | 2.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
CME Group
CME
$88.6B
| $180K | 0.13% |
918
+13
| +1% | +$2.69K |
|
127
Cboe Global Markets
CBOE
$29.1B
| $180K | 0.13% |
1,057
+8
| +0.8% | +$1.42K |
|
|
CIM
128
Chimera Investment
CIM
$1.06B
| $179K | 0.13% |
+14,023
| New | +$178K |
|
129
Assurant
AIZ
$13.6B
| $175K | 0.13% |
1,054
+521
| +98% | +$90.4K |
|
130
Vanguard Global ex-US Real Estate ETF
VNQI
$3.47B
| $171K | 0.13% |
4,225
-205
| -5% | -$8.47K |
|
131
TechnipFMC
FTI
$28.7B
| $171K | 0.13% |
6,522
+3,211
| +97% | +$82.7K |
|
132
Royal Caribbean
RCL
$76.7B
| $169K | 0.12% |
1,057
-242
| -19% | -$34.8K |
|
133
Viridian Therapeutics
VRDN
$2.05B
| $163K | 0.12% |
12,500
+6,500
| +108% | +$90K |
|
134
Vanguard Real Estate ETF
VNQ
$39.4B
| $160K | 0.12% |
1,915
-168
| -8% | -$13.9K |
|
135
Carnival Corporation Ltd
CCL
$35.7B
| $157K | 0.12% |
8,378
-478
| -5% | -$7.39K |
|
136
DraftKings
DKNG
$12.1B
| $150K | 0.11% |
3,938
+684
| +21% | +$28.4K |
|
137
iShares MSCI Taiwan ETF
EWT
$9.8B
| $132K | 0.1% |
2,431
-240
| -9% | -$12K |
|
138
iShares MSCI South Africa ETF
EZA
$530M
| $131K | 0.1% |
+3,014
| New | +$124K |
|
139
iShares MSCI India ETF
INDA
$6.78B
| $129K | 0.09% |
2,308
-111
| -5% | -$5.88K |
|
140
Vertiv
VRT
$112B
| $122K | 0.09% |
1,409
+16
| +1% | +$1.46K |
|
141
iShares MSCI Turkey ETF
TUR
$207M
| $122K | 0.09% |
2,894
-407
| -12% | -$16.5K |
|
142
iShares MSCI Malaysia ETF
EWM
$308M
| $120K | 0.09% |
5,326
-369
| -6% | -$8.31K |
|
143
iShares China Large-Cap ETF
FXI
$4.36B
| $119K | 0.09% |
+4,594
| New | +$121K |
|
144
iShares MSCI Poland ETF
EPOL
$661M
| $119K | 0.09% |
4,859
-450
| -8% | -$10.9K |
|
|
GREK
145
Global X MSCI Greece ETF
GREK
$279M
| $118K | 0.09% |
2,972
-113
| -4% | -$4.6K |
|
146
iShares MSCI South Korea ETF
EWY
$21.7B
| $118K | 0.09% |
1,780
-150
| -8% | -$9.66K |
|
147
United Rentals
URI
$63.4B
| $113K | 0.08% |
174
-251
| -59% | -$167K |
|
148
iShares MSCI Peru and Global Exposure ETF
EPU
$528M
| $112K | 0.08% |
2,790
-731
| -21% | -$30.2K |
|
149
Wells Fargo
WFC
$261B
| $112K | 0.08% |
1,883
-63
| -3% | -$3.72K |
|
150
HCA Healthcare
HCA
$82.2B
| $107K | 0.08% |
333
-321
| -49% | -$104K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q2 2024 Portfolio in Review
As of Q2 2024, AlphaCentric Advisors held 262 positions worth $136M, down 18% from $166M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
AlphaCentric Advisors withdrew a net $21.6M in Q2 2024, closing 45 positions and reducing 87 holdings. Its most notable exit was UroGen Pharma, an estimated $2.16M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 61% a quarter earlier, followed by Real Estate and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Enovis worth $904K.
- AlphaCentric Advisors's largest Q2 2024 buy was Enovis: 20,000 shares worth $904K.
- AlphaCentric Advisors added most to Invesco QQQ Trust in Q2 2024, an estimated $958K increase.
- AlphaCentric Advisors's biggest Q2 2024 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $2.13M.
- AlphaCentric Advisors fully exited UroGen Pharma in Q2 2024, selling an estimated $2.16M.
- AlphaCentric Advisors's ten largest holdings make up 25% of its $136M portfolio in Q2 2024.
- AlphaCentric Advisors opened 34 new positions and closed 45 in Q2 2024.
- AlphaCentric Advisors's portfolio value fell 18% quarter-over-quarter to $136M.
Based on AlphaCentric Advisors's 13F filing for Q2 2024, filed 25 Jul 2024.